<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343277">
  <stage>Registered</stage>
  <submitdate>29/07/2011</submitdate>
  <approvaldate>2/08/2011</approvaldate>
  <actrnumber>ACTRN12611000809932</actrnumber>
  <trial_identification>
    <studytitle>Analysis of hemodialysed patients immune response to anti - Hepatitis B vaccination performing dialysis with an high capacity adsorbent polymethylmethacrylate membrane</studytitle>
    <scientifictitle>Analysis of the effectiveness in clinical practice of the use of polymethylmethacrylate membrane dialyzer as adjuvant in the treatment of dialysis patients in the course of Hepatitis B vaccination</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>End Stage Renal Disease patients immune system response to Hepatitis B vaccination</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Analysis of the effectiveness in practice of the use of polymethylmethacrylate membrane dialyzers as adjuvant in the treatment of dialysis patients in the course of anti - Hepatitis B vaccination.

Arm1: patients on maintainance thrice-weekly dialysis resulting non responder to anti-Hepatitis B vaccination in accordance with Center for Desease Control (CDC) and prevention criteria and discontinuing their actual dialysis membrane switching to a polymethylmethacrylate membrane with high pore size and a enhanced absorptive capacity for at least four month, at the third month receiving a regular vaccine booster dose.

Arm2: patients on maintainance thrice-weekly dialysis resulting non responder to anti-Hepatitis B vaccine with CDC criteria not using any kind of polymetylmethacrilate membrane dialyzers, at the third month receiving a regular vaccine booster dose.

We intend to observe if there is any difference between the two groups in term of response to the vaccine booster dose.</interventions>
    <comparator>Standard dialysis treatment performed with non polymethylmethacrylate membrane dialyzer.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Efficacy of anti-Hepatitis B vaccination in patients treated with polymethylmethacrylates membrane dialyzers. We expect a difference in the two groups of more than 25% in the number of patients with positive antibody response (Ab HBs &gt; 10%) after the last dose of vaccine (booster).</outcome>
      <timepoint>Four months after starting observation period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Polymethylmethacrylate dialyzers are able decrease pre-dialysis serum level of sCD40 (soluble form of CD40)</outcome>
      <timepoint>Three months after starting observation period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>End Stage Renal desease patients on mainteinance thrice-weekly dialysis treatment who had been defined as non-responder to Hepatitis B vaccination according to CDC criteria</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>End Stage Renal desease patients on mainteinance thrice-weekly dialysis treatment who had been defined as non responder to Hepatitis B vaccination according to CDC criteria already using any kind of polymethylmethacrylate membrane dialyzers at the initial time of observation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment>the steering cometee prepares 40 closed envelopes ( 20 for the study group + 20 for the control group) and mixing up them</concealment>
    <sequence>opening closed envelops with group A (study group) and B (control group)</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>none</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>30/08/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>USL 8 Arezzo P.O. Ospedale S. Donato di Arezzo</primarysponsorname>
    <primarysponsoraddress>Ospedale San Donato, Via Pietro Nenni 20 - 52100 - Arezzo - Italy</primarysponsoraddress>
    <primarysponsorcountry>Italy</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>USL 8 Arezzo P.O. Ospedale S. Donato di Arezzo</fundingname>
      <fundingaddress>Ospedale San Donato, Via Pietro Nenni 20 - 52100 - Arezzo - Italy</fundingaddress>
      <fundingcountry>Italy</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Estor Spa</sponsorname>
      <sponsoraddress>Via Newton 12 - 20016 - Pero (MI) - Italy</sponsoraddress>
      <sponsorcountry>Italy</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Analysis of hemodialysed patients immune response to Anti Hepatitis B vaccination performing a dialysis treatment with a high capacity adsorbent polymethylmetacrylate dialyzer</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comitato Etico Locale (CEL), USL 8 Arezzo</ethicname>
      <ethicaddress>Ospedale San Donato, Via Pietro Nenni 20 - 52100 - Arezzo - Italy</ethicaddress>
      <ethicapprovaldate>21/06/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Patrizio Imperiali</name>
      <address>Ospedale San Donato di Arezzo - Via Pietro Nenni 20 - 52100 - Arezzo - Italy</address>
      <phone>+390575255439</phone>
      <fax />
      <email>patrizio.imperiali@usl8.toscana.it</email>
      <country>Italy</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Patrizio Imperiali</name>
      <address>Ospedale San Donato di Arezzo - Via Pietro Nenni 20 - 52100 - Arezzo - Italy</address>
      <phone>+390575255439</phone>
      <fax />
      <email>patrizio.imperiali@usl8.toscana.it</email>
      <country>Italy</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>